Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death. Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin.
The use of docetaxel may lead to udesired outcomes such as hepatic impairment, hematologic effects, enterocolitis and neutropenic colitis, hypersensitivity reactions, fluid retention, second primary malignancies, embryo-fetal toxicity, and tumor lysis syndrome. Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC. For the treatment of metastatic castration-resistant prostate cancer, docetaxel is indicated with prednisone. Docetaxel is also indicated with cisplatin and fluorouracil for untreated, advanced gastric adenocarcinoma, including the gastroesophageal junction, and with cisplatin and fluorouracil for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Centre Hospitalier René Dubos, Cergy Pontoise, France
Centre Hospitalier Du Mans, Le Mans, France
Centre Oscar Lambret, Lille, France
Medicine Branch, Bethesda, Maryland, United States
IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece
"Metaxa's" Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Piraeus, Greece
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
"Metaxa's" Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Athens, Greece
" General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases, Athens, Greece
Theagenion Anticancer Hospital of Thessaloniki, Thessaloniki, Greece
University General Hospital of Alexandroupolis, Department of Medical Oncology, Alexandroupolis, Greece
401 Military Hospital of Athens, Athens, Greece
GSK Investigational Site, Lebanon, New Hampshire, United States
University of Chicago, Chicago, Illinois, United States
Hematology-Oncology Associates Of Rockland, Nyack, New York, United States
Duke University, Durham, North Carolina, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.